



(86) Date de dépôt PCT/PCT Filing Date: 2004/07/19
(87) Date publication PCT/PCT Publication Date: 2005/01/27
(85) Entrée phase nationale/National Entry: 2006/01/10
(86) N° demande PCT/PCT Application No.: IB 2004/003096
(87) N° publication PCT/PCT Publication No.: 2005/007880
(30) Priorité/Priority: 2003/07/18 (US60/487,943)

(51) Cl.Int./Int.Cl. *C12Q 1/48* (2006.01),
C12Q 1/42 (2006.01), *C12Q 1/18* (2006.01)

(71) Demandeur/Applicant:
INSTITUT PASTEUR, FR

(72) Inventeurs/Inventors:
ALZARI, PEDRO, FR;
BOITEL, BRIGITTE, FR;
VILLARINO, ANDREA, FR;
FERNANDEZ, PABLO, FR;
COLE, STEWART, FR

(74) Agent: ROBIC

(54) Titre : PKNB KINASE ET PSTP PHOSPHATASE ET PROCEDES D'IDENTIFICATION DE SUBSTANCES
INHIBITRICES

(54) Title: PKNB KINASE AND PSTP PHOSPHATASE AND METHODS OF IDENTIFYING INHIBITORY SUBSTANCES

(57) **Abrégé/Abstract:**

The present invention relates to a pknB kinase and a pstP phosphatase as well as their use for identifying antibacterial substances.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007880 A1

(51) International Patent Classification⁷: **C12Q 1/48**,
1/42, 1/18

(21) International Application Number:
PCT/IB2004/003096

(22) International Filing Date: 19 July 2004 (19.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/487,943 18 July 2003 (18.07.2003) US

(71) Applicant (for all designated States except US): **INSTITUT PASTEUR** [FR/FR]; 25-28, rue du Docteur Roux, F-75015 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALZARI, Pedro** [IT/FR]; 141, rue de Vaugirard, F-75015 Paris (FR). **BOITEL, Brigitte** [FR/FR]; 37, rue de Sahel, F-75012 Paris (FR). **VILLARINO, Andréa** [UY/FR]; 198 bis rue Raymond Losserand, F-75014 Paris (FR). **FERNANDEZ, Pablo** [AR/FR]; 197, rue de Tolbiac, F-75013 Paris (FR). **COLE, Stewart** [GB/FR]; 23 bis, rue Cécile Dinant, F-92140 Clamart (FR).

(74) Agents: **MARTIN, Jean-Jacques** et al.; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

(48) Date of publication of this corrected version:

21 April 2005

(15) Information about Correction:

see PCT Gazette No. 16/2005 of 21 April 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PKNB KINASE AND PSTP PHOSPHATASE AND METHODS OF IDENTIFYING INHIBITORY SUBSTANCES

(57) Abstract: The present invention relates to a pknB kinase and a pstP phosphatase as well as their use for identifying antibacterial substances.

WO 2005/007880 A1

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

PKNB KINASE AND PSTP PHOSPHATASE AND METHODS OF IDENTIFYING
INHIBITORY SUBSTANCES

BACKGROUND OF THE INVENTION

5 FIELD OF THE INVENTION

The present invention relates to a pknB kinase and a pstP phosphatase as well as their use for identifying antibacterial substances.

DESCRIPTION OF THE BACKGROUND

10 Tuberculosis (TB) is a major public health problem with one-third of the world's population infected by its aetiologic agent, *Mycobacterium tuberculosis*, and over two million people dying from the disease each year (Dye *et al.*, 1999, *WHO Global Surveillance Monitoring Project J Am Med Assoc* **282**: 677-686). The Global Alliance for TB Drug Development has proposed that the current treatment could be improved considerably by developing more potent therapeutic agents, that reduce the duration of
15 therapy, and by including drugs that act on latent bacilli (Global Alliance for TB Drug Development. (2001) Scientific blueprint for tuberculosis drug development. *Tuberculosis* **81**: 1-52.). Faced with the urgency to develop new therapeutic strategies, it appears crucial to understand better the physiopathology of the causative agent and its complex relationship with the immune system of the host.

20 After inhalation, infectious bacilli are phagocytosed by alveolar macrophages in the lung and induce a local pro-inflammatory response, which leads to the recruitment of monocytes from the bloodstream into the site of infection (Dannenberg, A.M. (1999) Pathophysiology: basic aspects. In *Tuberculosis and Nontuberculous Mycobacterial Infections*. Schlossberg, D., (ed.). Philadelphia: W.B. Saunders Company, pp. 17-47;
25 Russell, 2001, Nature Rev Mol Cell Biol **2**: 569-577). By blocking fusion of phagosomes with lysosomes in these non-activated macrophages (Brown *et al.*, 1969, Nature **221**: 658-660; Sturgill-Koszycki *et al.*, 1996, EMBO J **15**: 6960-6968), *M. tuberculosis* escapes killing and multiplies. As the immune response progresses, macrophages and T cells accumulate to form a granuloma in which the pathogen is
30 contained in a latent state (Parrish *et al.*, 1998, TIBS **6**: 107-112; Manabe and Bishai, 2000, Nature Med **6**: 1327-1329). It can lie dormant for years only to rise again when the immune system wanes through old age, malnutrition or AIDS (acquired immuno-

deficiency syndrome). The centre of the granuloma then liquefies and *M. tuberculosis* replicates profusely and is discharged into the bronchial tree producing an infectious cough (Dannenber, 1999, Pathophysiology: basic aspects. In *Tuberculosis and Nontuberculous Mycobacterial Infections*. Schlossberg, D., (ed.). Philadelphia: W.B. Saunders Company, pp. 17-47). To understand the bacterial response to these changes in host environment, the study of regulatory proteins involved in mycobacterial signal transduction is therefore of the utmost importance.

Phosphorylation, a simple and efficient means of reversibly changing the biochemical properties of a protein, is a major mechanism for signal transduction and regulation of almost all biological functions. There are two main phosphorylative signal transduction systems. Prokaryotes predominantly use the two-component system, comprising in its simplest form a signal sensor with a histidine kinase domain and a response regulator, often a transcriptional factor (Wurgler-Murphy and Saito, 1997, *TIBS* **22**: 172-176; Stock et al., 2000, *Annu Rev Biochem* **69**: 183-215). This simple, unidirectional mechanism allows a quick response to abrupt environmental changes. The second system depends on the reversible phosphorylation of serine, threonine and tyrosine residues, and is widely used in eukaryotes (Hanks and Hunter, 1995, *FASEB J* **9**: 576-596; Hunter, 1995, *Cell* **80**: 225-236; Barford et al., 1998, *Annu Rev Biophys Biomol Struct* **27**: 133-164 ; Hunter, 2000, *Cell* **100**: 113-127). This mechanism involves the action of protein kinases and phosphoprotein phosphatases in cascades and networks (Hunter, 2000, *Cell* **100**: 113-127), providing an efficient means for the rapid modulation of the transduced signal to serve highly regulated functions.

Since the identification of the first bacterial homologue a few years ago (Muñoz-Dorado et al., 1991, *Cell* **67**: 995-1006), genomics has now demonstrated that serine, threonine and tyrosine protein kinases and phosphatases are also widespread in prokaryotes (Zhang, 1996, *Mol Microbiol* **20**: 9-15; Kennelly, 2002, *FEMS Microbiol Lett* **206**: 1-8). The two phosphorylation mechanisms (two-component systems and Ser/Thr/Tyr kinases and phosphatases) in prokaryotes may regulate distinct functions or act together in the same signalling pathway. The presence of Ser/Thr and Tyr kinases and phosphatases in prokaryotes appears to be associated with a complex, multistage developmental cycle and possible roles in regulating growth and development (heterocyst, fruiting-body or spore formation) have been proposed (Zhang, 1996, *Mol*

Microbiol **20**: 9-15; Shi et al., 1998, FEMS Microbiol Rev **22**: 229-253). The dormant state of *M. tuberculosis*, although poorly understood, may be considered in some regards analogous to sporulation (Demaio et al., 1996, Proc Natl Acad Sci USA **93**: 2790-2794) and thus involve these enzymes.

5 *Mycobacterium tuberculosis* employs both systems of protein phosphorylation. It has 15 sensor His kinases and 15 response regulators, forming at least 11 functional pairs, together with 11 putative Ser/Thr protein kinases (STPKs), one phospho-Ser/Thr phosphatase (*ppp* renamed here *pstP*) and two Tyr phosphatases (*ptpA*, *ptpB*) (Cole et al., 1998, Nature **393**: 537-544). There appears to be no counterpart Tyr kinase for
10 the two Tyr phosphatases, PtpA and PtpB, which can, moreover, be secreted (Koul et al., 2000, Microbiology **147**: 2307-2314; Cowley et al., 2002, Res Microbiol **153**: 233-241). Eight of the 11 STPKs are predicted to be transmembrane proteins, with a putative extracellular signal sensor domain and an intracellular kinase domain. Six STPKs (PknA, B, D, E, F, G) have already been expressed as recombinant proteins and shown
15 to be functional kinases (Peirs et al., 1997, Eur J Biochem **244**: 604-612; Av-Gay et al., 1999, Infect Immun **67**: 5676-5682; Koul et al., 2001, J Bacteriol **182**: 5425-5432; Chaba et al., 2002, Eur J Biochem **269**: 1078-1085; data not shown for PknE).

At this time, no physiological role has been clearly demonstrated for any of the STPKs or phosphatases from *M. tuberculosis*, and knock-out mutants have not yet been
20 reported.

In view of the above, there remains a need for developing new targets and therapies for mycobacterial infections.

SUMMARY OF THE INVENTION

BRIEF DESCRIPTION OF THE DRAWINGS

25 **Figure 1:** Conserved structure of the putative operon including the *pknB* and *pstP* genes in several actinobacteria. The genes coding for the following signal transduction elements, PknA, PknB, PstP and two proteins with a FHA domain, are co-localized with two genes involved in peptidoglycan synthesis, namely *pbpA* and *rodA*. This gene cluster is conserved in all actinobacteridae genomes known to date, including those
30 presented here, *M. tuberculosis*, *M. leprae*, *C. glutamicum* and *S. coelicolor* (note that the *pknA* gene is missing in *S. coelicolor* genome) and also such as *C. diphtheriae*, *C. efficiens*, *Thermobifida fusca* and *Bifidobacterium longum*.

Figures 2A and 2B:

Figure 2A. Structural organization of PstP. JM; juxta-membrane region, TM; *trans*-membrane region.

Figure 2B. Primary sequence alignment of the catalytic domain of PstP and the
5 human PP2C (SEQ ID NOS: 1 and 2) conserved residues are boxed. The amino acids of
PP2C involved in the binding of the metal ions and the phosphate are indicated with a
star. Secondary structural elements are indicated above the sequence.

Figures 3A to 3C:

Figure 3A. Purification to homogeneity of PstP₁₋₂₄₀. His-tagged PstP₁₋₂₄₀ was
10 purified by affinity and size exclusion chromatography. The purity was then checked by
SDS-PAGE electrophoresis. PstP₁₋₂₄₀ appears as a single discrete band on the gel with
an apparent MW (32 kDa) slightly higher than the expected value (27.6 kDa).

Figures 3B and 3C. Analysis of the specificity of PstP₁₋₂₄₀ towards
phosphoresidues. MBP (figure 3B) and α -casein (figure 3C) were phosphorylated either
15 on serine and threonine residues or on tyrosine residues with [γ -³³P]ATP. Release of
radiolabelled inorganic phosphate was measured after incubation of increasing
concentrations of the purified PstP₁₋₂₄₀ with the different phosphosubstrates.

Figures 4A and 4B:

Figure 4A. Structural organization of PknB.

Figure 4B. Sequence alignment of the putative sensor domain of bacterial
20 STPKs. A BLAST search was conducted to detect the protein sequences most similar to
the PknB C-terminal domain. We then selected among them the nine STPKs most
similar to *M. tuberculosis* PknB, i.e. STPKs from *M. leprae*, *Corynebacterium*
glutamicum, *C. efficiens*, *Thermobifida fusca*, *Bifidobacterium longum*, *Streptomyces*
25 *coelicolor* and *Bacillus subtilis* (SEQ ID NOS: 3-12). The sequences of the C-terminal
domains of these proteins were aligned with CLUSTALW. The extracellular domain of
these STPKs consists of three to four PASTA domains, represented as different blocks.
These repeated domains may have arisen by duplication events.

Figures 5A and 5B:

Figure 5A. Kinase activity of PknB₁₋₂₇₉: autophosphorylation and MBP
30 phosphorylation assays. Purified PknB₁₋₂₇₉, alone or with the model kinase substrate
MBP, was incubated with [γ -³³P]ATP in the presence or absence of MnCl₂. The reaction

products were resolved on a SDS-PAGE gel that was Coomassie blue stained (left panel) then dried and autoradiographed (right panel). As observed for other phosphoproteins, the apparent MW of the protein in SDS-PAGE (40 kDa) is significantly higher than the expected value of 32 kDa. Effect of divalent cations on the kinase activity of PknB₁₋₂₇₉. Various concentrations of MnCl₂ or MgCl₂ were used in the MBP phosphorylation assay. Relative quantification of the incorporated phosphate on MBP was obtained after PhosphorImager analysis.

Figures 6A and 6B: MALDI spectra of PknB before (figure 6A) and after (figure 6B) dephosphorylation with alkaline phosphatase.

Figures 7A to 7C: Dephosphorylation assay using PknB₁₋₂₇₉ as a substrate for PstP₁₋₂₄₀ and effect of the dephosphorylation of PknB₁₋₂₇₉ by PstP₁₋₂₄₀ on its kinase activity.

Figure 7A. Autophosphorylated PknB₁₋₂₇₉ in presence of [γ -³³P]ATP was used as substrate for PstP₁₋₂₄₀. As a control, MnCl₂ was omitted from the reaction buffer. The products of the reaction were subjected to electrophoresis on a denaturing gel. Left panel: the Coomassie blue stained gel; right panel: the autoradiograph.

Figure 7B. Without prior labelling, dephosphorylation of PknB is followed with the shift in protein migration in SDS-PAGE.

Figure 7C. PknB₁₋₂₇₉ was preincubated with or without PstP₁₋₂₄₀ for the indicated time. The kinase activity was then assayed using MBP and thio- γ ATP as substrates. Relative quantification of the kinase activity obtained with the PhosphorImager was plotted.

Figures 8A to 8C: Identification of phosphorylation sites in PknB₁₋₂₇₉.

Figure 8A. HPLC separation of tryptic digests from PknB₁₋₂₇₉ before (upper panel) and after treatment with PstP (lower panel). Fractions were manually collected and analysed by MALDI-MS, with partial sequencing by PSD-MS when necessary for conclusive peptide identification. Only peptides relevant to this work are annotated in the chromatograms: peak 1, monophosphorylated His-tag peptide ($m/z = 1848.61$, calc. monoisotopic mass = 1848.84); peak 2, His-tag peptide ($m/z = 1768.91$, calc. monoisotopic mass = 1768.84, sequence GSSHHHHHHSSGLVPR-SEQ ID NO:13); peak 3, diphosphorylated S162-R189 peptide ($m/z = 2979.17$, calc. monoisotopic mass = 2979.34); and peak 4, S162-189 peptide ($m/z = 2819.53$, calc. monoisotopic mass = 2819.41).

Figure 8B. Detailed PSD spectra obtained with a sample from peak 3. The signals corresponding to -80 Da, -98 Da, -(80 + 98) Da, -(98 + 98) Da are strongly indicative of presence of two phosphate groups in serine and/or threonine residues in the analysed sample.

5 Figure 8C. Integrated PSD spectra to confirm peptide identification by sequencing (SEQ ID NO: 14) and to localise phosphorylated residues (measured values from the y -ion series in Da: $y_3 = 374.0$; $y_5 = 600.1$; $y_6 = 687.2$; $y_7 = 799.8$; $y_8 = 962.0$; $y_9 = 1091.0$; $y_{10} = 1162.3$; $y_{11} = 1262.5$; $y_{12} = 1319.4$; $y_{13} = 1433.1$; $y_{14} = 1533.2$; $y_{15} = 1603.3$; $y_{16} = 1674.4$; $y_{17} - 98 = 1757.3$; $y_{18} - 98 = 1886.1$; $y_{19} - 98 - 98 = 1969.0$; $y_{19} - 98 =$
10 2067.4 ; $y_{19} = 2165.4$).

Figures 9A and 9B: The putative phosphate-binding site in PknB.

Figure 9A. Surface representation of PknB (PDB code 1O6Y) colour-coded according to charge. A cluster of four exposed arginine residues could provide a binding site for the two phosphorylated threonine residues, Thr171 and Thr173. Sixteen residues
15 from the activation loop (connecting Ile163 to Ala180 and including the two phosphothreonines) are disordered in the crystal structure.

Figure 9B. Equivalent view of mouse PKA (PDB code 1ATP), in which the region corresponding to that missing in PknB is shown in stick representation. The phosphate group of phospho-Thr197 makes hydrogen-bonding interactions with the side
20 chains of two arginine and one histidine residues.

Figure 10: Kinase activity of the activation loop mutants of PknB. MBP phosphorylation assays have been performed in parallel for the alanine mutants and the wild-type PknB₁₋₂₇₉. Relative quantification of the kinase activity was obtained with the PhosphorImager: T171A, T173A and T171/173 A mutants are ≈ 15 , 20, and 300 times
25 less active than PknB₁₋₂₇₉ respectively.

DETAILED DESCRIPTION OF THE INVENTION

The *pknB* and *pstP* genes along with *pknA* are found in an operon (Fig. 1) that also includes *rodA* and *pbpA* (Cole *et al.*, 1998, *Nature* 393: 537-544), two genes encoding morphogenic proteins involved in peptidoglycan synthesis during cell growth
30 (Matsubishi, 1994, Utilization of lipid-linked precursors and the formation of peptidoglycan in the process of cell growth and division. In *Bacterial Cell Wall*. Ghuyssen, J.-M., and Hakenbeck, R., (eds). Amsterdam-London: Elsevier). Furthermore,

this genomic region remains unchanged in the close relative *M. leprae* (Fsihi *et al.*, 1996, *Microbiology* **142**: 3147-3161), in spite of the extensive gene decay in this bacillus which has removed or inactivated over 2400 genes including those for all other STPKs (except for PknL and PknG) and both Tyr phosphatases (Eiglmeier *et al.*, 2001, *Leprosy Rev* **72**: 387-398). Thus, the conservation of the *pknA*, *pknB* and *pstP* genes near the chromosomal origin of replication in *M. leprae* strongly suggests that the corresponding enzymes could regulate essential functions, possibly related to cell growth or latency of mycobacteria.

We demonstrate here that Pstp dephosphorylates specifically phospho-Ser/Thr residues and that its activity is strictly dependent on the presence of divalent cations. We also report that the catalytic domain of PknB, as defined by homology modelling, is an active protein kinase in its phosphorylated state. Pstp is capable of dephosphorylating PknB, which subsequently exhibits decreased kinase activity. Mass spectrometry analysis identified two phosphothreonine residues in the activation loop of PknB. Mutagenesis of these threonines in alanine demonstrate their role in regulating PknB kinase activity. Thus, Pstp and PknB could interplay *in vivo* in the same transduction pathway, and discuss the putative regulatory roles of these enzymes in mycobacteria.

In prokaryotes, genes involved in the same cellular process are frequently clustered often forming an operon. Thus, co-localization of the *pknB* and *pstP* genes in the same genomic region (Fig. 1) reinforces the hypothesis that these enzymes can intervene in the same signal transduction pathway. Furthermore, the organization of this genomic region suggests the participation of additional signal transduction elements, including a second STPK (namely PknA) and two proteins harbouring FHA domains (Rv0019c and Rv0020c), all of which are also conserved in other actinobacteria (Fig. 1). The FHA domains are small (Å 130 aa) protein modules that mediate protein-protein interaction via the recognition of a phosphorylated threonine on the target molecule (Durocher and Jackson, 2002, *FEBS Lett* **513**: 58-66). In eukaryotes, they are present in numerous signalling and regulatory proteins such as kinases, phosphatases, RNA-binding proteins and transcription factors. Rv0019c (155 aa) corresponds to a single FHA domain whereas Rv0020c (527 aa) has two domains, a Ct FHA domain and a Nt domain that shows no homology with any known protein except with its orthologue in *M. leprae* (ML0022). The FHA domain of Rv0020c has recently been characterized for

its ability to bind phosphorylated peptide ligands (Durocher *et al.*, 2000, *Mol Cell* 6: 1169-1182).

Also found in the same conserved operon (Fig. 1) are two genes, *pbpA* and *rodA*, encoding proteins involved in controlling cell shape and peptidoglycan synthesis during cell growth (Matsuhashi, 1994, Utilization of lipid-linked precursors and the formation of peptidoglycan in the process of cell growth and division. In *Bacterial Cell Wall*. Ghuysen, J.-M., and Hakenbeck, R., (eds). Amsterdam-London: Elsevier). Cell growth and development require the cell wall to have a dynamic structure. Indeed, the cell wall changes continuously, during growth and developmental processes such as sporulation, and in response to changes in the environment. Moreover, morphological adaptation like cell wall thickening could be an important determinant for survival of the slow-growing pathogenic mycobacteria in anaerobiosis (Cunningham and Spreadbury, 1998, *J Bacteriol* 180: 801-808). Cross-linked peptidoglycan, a major component of the bacterial cell wall, is synthesized by penicillin-binding proteins (PBP), which are membrane anchored enzymes with two external catalytic modules. Some PBPs are only involved in specific phases of growth or development and, for transglycosylase activity, they are each associated with a membrane protein partner. Thus in *E. coli*, PBP2 and RodA are responsible for peptidoglycan synthesis during cell elongation and for determination of the rod shape, whereas PBP3 and FtsW are involved in peptidoglycan synthesis during cell division (septation). In *B. subtilis*, a homologous couple (PBP and SpoVE) is thought to be engaged in spore formation.

Therefore, PknA, PknB and PstP, along with other signalling modulators, coordinately regulate cell elongation during growth. Indeed, recent data suggest a regulatory role for PknA in cell elongation (Chaba *et al.*, 2002, *Eur J Biochem* 269: 1078-1085) and it has been speculated that the extracellular domain of PknB could bind unlinked peptidoglycan (Yeats *et al.*, 2002, *TIBS* 27: 438-440). Kinases and phosphatase might have opposing effects on the control of such a complex integrated pathway. Tight regulation of the process of cell elongation could therefore be a key element in mycobacterial development and provide a link between the intra/extracellular growth phase and the latent lifestyle within the granuloma. The data presented herein support the targeting of the signaling modulators described herein for the development

of antibacterial agents, e.g., antitubercular that are capable of targeting *M. tuberculosis* in the different stages of its life cycle.

The pstp2 phosphatase in the present invention comprises an amino acid sequence as set forth in SEQ ID NO: 1. The pknB protein kinase in the present invention comprises an amino acid sequence as set forth in SEQ ID NO: 3. Polynucleotides encoding the amino acid sequences can be readily ascertained using the known genetic code and degeneracy of the code.

In one embodiment, the proteins that are at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, and at least 99% identical to the pstp2 and pknB amino acid sequences or the polynucleotides encoding the amino acid sequences described herein are also included in the present invention. Preferably, the proteins have protein kinase or phosphatase activity as appropriate according to the description herein. Such proteins retain at least 5%, 10%, 15%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or can have greater than 100% of the protein kinase or phosphatase activities as described herein.

These polynucleotides can hybridize under stringent conditions to the coding polynucleotide sequences of the pknB and pstp2 amino acid sequences. The terms "stringent conditions" or "stringent hybridization conditions" includes reference to conditions under which a polynucleotide will hybridize to its target sequence, to a detectably greater degree than other sequences (e.g., at least 2-fold over background). High stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C., and a wash in 0.1X SSC at 60 to 65°C. Amino acid and polynucleotide identity, homology and/or similarity can be determined using the ClustalW algorithm, MEGALIGN™, Lasergene, Wisconsin).

The polynucleotides encoding the pknB and pstp2 proteins can be in a single polynucleotide molecule, e.g., a vector or in separate polynucleotide molecules. In one embodiment, the polynucleotides encoding the pknB and pstp2 proteins are present on one polynucleotide molecule, e.g., in a bacterial operon. A polynucleotide encoding the pknB and pstp2 proteins can also comprise rodA (SEQ ID NO: 19) and/or pbpA genes (SEQ ID NO: 20) in the same polynucleotide, e.g., vector. The polynucleotides may also be present in a recombinant bacterial host cell, for example, *E. coli*. or mycobacterium (e.g., *Mycobacterium tuberculosis*). In such bacterial cells, the genes

can be expressed from a single polynucleotide, e.g., vector or operon; or can be expressed separately from each other; as well as combinations of two or three with the remaining proteins being expressed on a separate polynucleotide.

One embodiment of the present invention is to screen for substances that modulate the activity of one or both of the *pknB* and *pstp2* proteins described herein. Substances that modulate the activity of one or both of the *pknB* and *pstp2* can be used as an antibacterial agent, and particularly, for treating infections caused by a mycobacterium such as, for example, *Mycobacterium tuberculosis*. The method of screening for substances comprises contacting a host cell comprising one or both of the *pknB* and *pstp2* proteins described herein, measuring the protein kinase and/or phosphatase activity of one or both of the *pknB* and *pstp2* proteins, and comparing the activity of one or both of the *pknB* and *pstp2* proteins in the host cell prior to contacting or in a control host cell that has not been contacted with the substance. A change in relative activity of one or both of the *pknB* and *pstp2* proteins indicates that the substance is effective in modulating those activities.

So, the present invention also comprises a method for identifying a substance which modulates the activity of a *pknB* protein kinase, comprising:

contacting a recombinant bacterial cell with the substance, wherein the recombinant bacterial cell expresses the *pknB* protein kinase, and wherein the *pknB* protein kinase comprises the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that is at least 70%, or 75%, 80%, 85%, 90%, 95% and 98%, identical to SEQ ID NO: 3 and has protein kinase activity;

measuring the *pknB* protein kinase activity from said bacterial cell; and

comparing the *pknB* protein kinase activity from the recombinant bacterial cell contacted with the substance to a bacterial cell which has not been contacted with the substance, wherein a change in protein kinase activity from the recombinant bacterial cell contacted with the substance relative to a bacterial cell which has not been contacted with the substance indicates that the substance modulates the activity of *pknB* protein kinase.

In another aspect, the present invention also comprises a method for identifying a substance which modulates the activity of a *pstp2* phosphatase, comprising:

contacting a recombinant bacterial cell with the substance, wherein the recombinant bacterial cell expresses the pstp2 phosphatase, and wherein the pstp2 phosphatase comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 70%, or 75%, 80%, 85%, 90%, 95% and 98%, identical to SEQ ID NO: 1 and has phosphatase activity;

measuring the pstp2 phosphatase activity from the recombinant bacterial cell; and

comparing the pstp2 phosphatase activity from the recombinant bacterial cell contacted with the substance to a bacterial cell which has not been contacted with the substance, wherein a change in phosphatase activity from the recombinant bacterial cell contacted with the substance relative to a bacterial cell which has not been contacted with the substance indicates that the substance modulates the activity of pstp2 phosphatase.

In another embodiment, the substances identified above, can be tested for antibacterial activity, for example, inhibiting mycobacterium, preferably *M. tuberculosis*. The method would involve contacting a cell or a population of cells to be tested with the substance and determine whether the growth and/or survival of the bacterial cell or cells are impaired compared to a cell or cells that are not contacted with the substance or the same bacterial cell or cells prior to being contacted with the substance. Any appreciable impairment is indicative that the substance possesses antibacterial activity.

The substance(s) identified above can be synthesized by any chemical or biological method.

The substance(s) identified above can be prepared in a formulation containing one or more known physiologically acceptable diluents and/or carriers. The substance can also be used or administered to a mammalian subject in need of antibacterial treatment, for example, a human infected with *M. tuberculosis*.

EXAMPLES

EXPERIMENTAL PROCEDURES

Sequence analysis and modeling

For biochemical and structural (Ortiz-Lombardía et al., 2003, J Biol Chem 278: 13094-13100) studies, the catalytic kinase core of PknB was originally defined using a homology modelling approach. The 10 closest sequences from the Protein Data Bank

were selected, and a multiple alignment was carried out using CLUSTALW. After manual editing of the alignment, the five sequences sharing highest identity with PknB (namely *C. elegans* Twitchin kinase, rabbit phosphorylase kinase, mouse PKA, and human CDK6 and CDK2) were used as templates for homology modelling. Using different combinations of these templates various families of models were constructed and refined with the program MODELLER (v. 4.0). A comparison of the most self-consistent models allowed us to identify Gly 279 as the likely end point for the α -helix I defining the C-terminus of the kinase catalytic core.

Cloning and mutagenesis

10 Cosmid MTCY10H4 containing *pknB* (Rv0014c) and *pstP* (Rv0018c) was used in subcloning experiments. A PknB construct corresponding to the putative cytoplasmic domain (catalytic domain + juxtamembrane sequence - aa 1-331) was first obtained, as some regions outside the kinase core could stabilize the catalytic domain. The following primers were used for PCR amplification: forward primer (with *NdeI* site): 5'-
15 GATAGCCATATGACCACCCCTTCC-3' (SEQ ID NO: 15) and reverse primer (5'-TAA codon +*HindIII* site): 5'-AAACCGAAGCTTAACGGC CCACCG-3' (SEQ ID NO: 16). The digested and purified PCR product was ligated into the pET28 expression vector using the engineered *NdeI* and *HindIII* sites. PknB₁₋₃₃₁ was expressed as a broad heterogeneous protein, probably reflecting heterogeneity of its phosphorylation state as
20 various phosphorylated residues were detected in the juxtamembrane region (data not shown). A shorter construct corresponding to the core catalytic domain (aa 1-279) was thus obtained, introducing a stop codon by site-directed mutagenesis. PknB mutants (T171A, T173A, T171/173A) were all obtained from this last construct by the same method.

25 The complete *pstP* gene was subcloned into pET28 expression vector using the following primers: forward primer (with *NdeI* site): 5'-CGGGGGCATATGGC GCGCGTGA-3' (SEQ ID NO: 17) and reverse primer (TAA codon +*HindIII* site): 5'-GCAGTCGTAAGCTTATGCCGCG-3' (SEQ ID NO: 18). The construct corresponding to the catalytic domain of PstP (aa 1-240) was then obtained by
30 introducing a stop codon through site-directed mutagenesis.

All mutagenesis was done according to the Quick Change Stratagene procedure. Enzymes were purchased as follows: the T4 DNA ligase, *NdeI* and *DpnI* restriction

enzymes from Biolabs, *Hind*III and *Bgl*III restriction enzymes from Pharmacia, the *Pfu* and *Pfu* turbo polymerases from Stratagene. All constructs were verified by DNA sequencing.

Protein expression and purification

5 *Escherichia coli* BL21 (DE3) bacteria transformed with the appropriate plasmid were grown at 37°C until late log phase in Luria-Bertani (LB) medium with antibiotic (kanamycin 30 µg ml⁻¹). Induction of expression was conducted for 12-16 h at low temperature (15°C) after addition of 1 mM IPTG. Bacterial pellet was resuspended in
10 50 mM Hepes buffer pH7, 0.2M NaCl, in the presence of protease inhibitors and sonicated. The lysate was cleared by centrifugation (20 000 g, 30 min to 1 h). The supernatant containing soluble proteins was applied to Ni-column (Pharmacia) using an FPLC system and eluted by an imidazol gradient (0-0.5M). A further step of gel filtration (Superdex 75) was required to separate the aggregated material from the monomeric proteins and to remove imidazol and most of the Ni²⁺ cations. Proteins were
15 subsequently concentrated by means of Macro- and Micro-sep concentrators (Pall/Gellman). Protein concentration was determined using the Bio-Rad protein assay. Purity of the samples was checked by SDS-PAGE electrophoresis.

Protein kinase assays

The kinase assays were carried out in 20 µl of kinase buffer (Hepes 50 mM pH7,
20 DTT 1 mM, Brij35 0.01%) containing 2 mM MnCl₂, 100 µM ATP and 1 µCi of [γ -³³P]-ATP. For the analysis of divalent cation preference various concentrations of MnCl₂ or MgCl₂ were used, as indicated in the figure 5B. For autophosphorylation 5 µM final of the purified PknB was used. For phosphorylation of the MBP substrate by PknB or the PknB mutants, the enzyme/substrate ratio was 1:20 with 0.5 µM kinase. The reaction
25 was started with the addition of the kinase and conducted at 30°C for 10 min. For the kinetics of MBP phosphorylation by PknB and the PknB mutants, 10 µl-aliquots of a scaled-up 60 µl reaction mixture were withdrawn at each indicated time. The reaction was stopped by the addition of SDS-PAGE sample buffer plus EDTA (25 mM final). Ten µl of the reaction were subjected to electrophoresis. In each case, the reaction
30 products were separated on a 12% SDS-polyacrylamide gel and the radiolabelled proteins visualized by auto-radiography. To obtain relative quantification of the incorporation of radiolabelled ATP, the radioactive samples were also analysed using a

PhosphorImager apparatus (STORM, Molecular Dynamics). For testing kinase activity of PknB after various incubation times with PstP, ATP and $[\gamma\text{-}^{33}\text{P}]\text{ATP}$ were replaced by thio- γATP and $[\text{}^{35}\text{S}]\text{ATP-}\gamma\text{S}$ respectively. $[\gamma\text{-}^{33}\text{P}]\text{ATP}$ and $[\text{}^{35}\text{S}]\text{ATP-}\gamma\text{S}$ were purchased from AmershamBiosciences. MBP was from Invitrogen.

5 Protein phosphatase assays

Dephosphorylation of phosphoSer/Thr or phosphoTyr proteins by PstP was assayed using either MBP or α -casein (SIGMA). Phosphorylated $[\text{}^{33}\text{P}]\text{Ser/Thr}$ -substrates or $[\text{}^{33}\text{P}]\text{Tyr}$ -substrates were prepared by phosphorylation of the proteins using either the catalytic subunit of PKA or the Abl protein tyrosine kinase. In each case, the
10 kinase reaction was performed in 200 μl of buffer (50 mM Hepes pH7.5, 5 mM MgCl_2 , 1 mM EGTA, 2 mM DTT, 0.01% Brij35) with 1 mM ATP, 75 μCi $[\gamma\text{-}^{33}\text{P}]\text{ATP}$, 200 μM substrate and 25 units of PKA or 10 units of Abl kinase. The reaction was incubated for 5 h at 30°C. Phosphorylated substrate was recovered by TCA precipitation and extensively dialysed at 4°C against a 25 mM Tris buffer pH7.5 with 0.1 mM EDTA, 2
15 mM DTT and 0.01% Brij35. Dephosphorylation assays were carried out in a 25 μl reaction mixture containing 50 mM Hepes buffer pH 7.5, 0.1 mM EDTA, 1 mM DTT and 0.01% Brij35, 5 mM MnCl_2 . Phosphorylated $[\text{}^{33}\text{P}]$ substrates were used to a final concentration corresponding to 10 μM of incorporated phosphates. The reaction was started with the addition of various concentrations of the purified PstP (up to 200
20 ng/25 μl , \approx 0.3 μM) and incubated for 10 min at 30°C. The reaction was terminated by adding cold 20% TCA. After centrifugation, soluble materials were added to scintillation fluid and counted for the release of inorganic phosphate. The serine/threonine phosphatase PP1 and the Tyrosine phosphatase T-Cell PTP were used as control for the dephosphorylation of the phosphoSer/Thr substrates and the
25 phosphoTyr substrates, respectively (not shown). The dephosphorylation of PknB by PstP was first performed using autophosphorylated $[\text{}^{33}\text{P}]\text{-PknB}$ that was prepared according to the above protocol, except that no extra kinase was added. The reaction was performed in 15 μl of Hepes buffer 50 mM pH7, DTT 1 mM, Brij35 0.01% with 2 mM MnCl_2 . $[\text{}^{33}\text{P}]\text{-PknB}$ and PstP were used at 5 μM and 1 μM , respectively, and
30 incubated 30 min at 30°C. The reaction products were resolved on a SDS-PAGE gel and the lost of labelling was visualized on the auto-radiography of the dried gel. The dephosphorylation of PknB by PstP was also simply assayed by the appearance of a

lower band on a gel corresponding to dephosphorylated PknB. The reaction was carried out in 10 μ l of the same buffer for 10 min at 30°C, except that PknB substrate was used at 1 μ M, various concentrations of the phosphatase PstP were added from 50 to 300 nM.

Mass spectrometry analysis

5 Identification of phosphorylated sites was performed by mass measurements in whole peptide mixtures and in purified HPLC fractions of proteins digested with trypsin (Promega, 0.5 μ g per 20-50 μ g of protein sample in 50 mM ammonium bicarbonate buffer, pH 8.4, overnight incubation at 35°C). Twenty-six tryptic peptides covering 90% of the PknB₁₋₂₇₉ sequence were thus identified (data not shown), whereas digestion
10 peptide products smaller than five amino acid residues could not be detected. In some experiments proteins were treated with a phosphatase before proteolytic cleavage: alkaline phosphatase from Roche Diagnostics (20 enzyme units per 20-40 μ g of protein incubated in an assay mixture according to instructions supplied by the manufacturer, for 1 h at 35°C) or purified PstP enzyme as described elsewhere in this section.

15 MALDI-TOF MS was carried out in a Voyager DE-PRO system (Applied Biosystems) equipped with a N₂ laser source ($\lambda = 337$ nm). Mass spectra were acquired for positive ions in linear and reflector modes at an accelerating voltage of 20 kV. The matrix was prepared with α -cyano-4-cinnamic acid for peptides or with sinnapinic acid for proteins, as saturated solutions in 0.2% trifluoroacetic acid in acetonitrile-H₂O (50%,
20 v/v). Measurement of peptide masses in reflector mode was performed under conditions of monoisotopic resolution with the accuracy close to 50 p.p.m. attained with external calibration. For this purpose a mixture of the following peptide mass standards was included ([MH]⁺ monoisotopic mass, concentration): angiotensin I (1296.68, 2 pmol μ l⁻¹); ACTH 1-17 clip (2093.08, 2 pmol μ l⁻¹); ACTH 18-39 clip (2465.20, 1.5 pmol μ l⁻¹); and ACTH 7-38 clip (3657.93, 3 pmol μ l⁻¹). Better accuracy was obtained when
25 internal mass calibration was sometimes performed with already characterised peptides present in PknB tryptic digests. For mass measurements of PknB proteins in linear mode, enolase of Baker's yeast (average mass of the protonated molecular ion [MH]⁺ = 46.672, and [MH₂]⁺² = 23.336) was used as a calibration standard. Samples for MS
30 were usually prepared by spotting 0.5 μ l of matrix solution and 0.5 μ l of peptide solution, or tiny droplets from a desalting microcolumn eluted with matrix solution (see below), directly on the sample plate.

Selected peptides isolated from HPLC runs were sequenced by PSD-MS analysis of the γ -ion series generated from the samples (Kaufmann *et al.*, 1993, *Rapid Commun Mass Spectrom* 7: 902-910), following instructions provided by the instrument manufacturer. When additional data were required to confirm a phosphorylation site by MS sequencing, the corresponding tryptic peptide was submitted to Ba(OH)₂ treatment for dephosphorylation of serine or threonine residues, following published procedures (Resing *et al.*, 1995, *Biochemistry* 34: 9477-9487).

HPLC separations were performed in a reverse-phase column (Vydac C18, 150 x 2.1 mm) equilibrated with 0.1% trifluoroacetic acid in H₂O (solvent A), and eluted with a gradient of 0.07% trifluoroacetic acid in acetonitrile (solvent B). Chromatographic conditions were as follows: flow rate 0.2 ml min⁻¹; chart paper 2 mm min⁻¹; gradient was from 0 min to 20 min up to 10% B, from 20 min to 100 min up to 30% B, from 100 min to 110 min up to 50% B, from 110 min to 115 min up to 100% B, and then 100% B isocratic for 5 min more; detection was by UV recording at 220 nm.

Relative amounts of the tryptic peptide A162-R189 showing different degrees and patterns of phosphorylation were calculated for wild-type and mutant PknB enzymes (Table 1). Peak size of purified and identified HPLC peaks (according to MS and PSD-MS measurements) was measured and corrected according to the chromatographic response of each peptide, tested in advance under identical chromatographic conditions as described above.

For mass measurements, HPLC fractions were sometimes concentrated under a N₂ gas flow, freeze-dried, or immobilised on reverse-phase Poros 10 R2 beads (Applied Biosystems). The latter was also a useful procedure to desalt small peptide or protein samples in batch or in home-made microcolumns (Gobom *et al.*, 1999, *J Mass Spectrom* 34: 105-116). Virtual tryptic digestions and other mass calculations were performed with the GPMAW32 (v.4.02) program (Lighthouse Data).

RESULTS

PstP is a Ser/Thr protein phosphatase

The *pstP* gene (Rv0018c) encodes a putative transmembrane protein of 514 aa (Cole *et al.*, 1998, *Nature* 393: 537-544) with a C-terminal extracellular domain (196 aa) rich in proline and serine residues (Fig. 2A). The putative intracellular domain (301 aa) is homologous to members of the eukaryotic Ser/Thr protein phosphatase PPM

family (Bork *et al.*, 1996, *Protein Sci* 5: 1421-1425). The sequence alignment of the catalytic domains of PstP and human PP2C, the prototype member of the PPM family, is shown in Figure 2B. Although PstP displays only 17% identity with the human enzyme, all the motifs corresponding to key structural elements (Bork *et al.*, 1996, *Protein Sci* 5: 1421-1425) are present in the PstP sequence. The crystal structure of the human PP2C has revealed a metal ion-catalysed dephosphorylation mechanism (Das *et al.*, 1996, *EMBO J* 15: 6798-6809). As indicated in Figure 2B, all the residues involved in the binding of metal cations and phosphate are conserved in PstP, suggesting a common mechanism of phosphate recognition and catalysis.

The multiple alignment of PstP with other members of the PPM phosphatase family predicted Asp 240 as the last residue of the catalytic domain. Thus, the His-tagged construction PstP₁₋₂₄₀ was produced as a soluble protein in *E. coli* (Figure 3A). The protein phosphatase activity and the specificity towards phospho-amino acids were tested using different substrates. The myelin basic protein (MBP) and α -casein were phosphorylated either on serine and threonine residues with the protein kinase A (PKA) or on tyrosine residues with the Abl kinase using radiolabelled ATP. As shown in Figures 3A and 3B, PstP dephosphorylated phospho-Ser/Thr substrates but showed little or no activity with phospho-Tyr substrates. Furthermore, PstP phosphatase activity was strictly dependent on divalent cations with a preference for Mn²⁺ versus Mg²⁺ (data not shown). Thus, in agreement with sequence homology-based predictions, these results demonstrate that the intracellular region of PstP is a Ser/Thr protein phosphatase that belongs to the PPM family.

The C-terminal domain of PknB is similar to that found in various other bacterial STPKs

PknB is predicted to be a 626 aa transmembrane protein with an intracellular N-terminal kinase domain (331 aa) and an extracellular C-terminal domain (276 aa) (Figure 4A). This structural organization for STPKs is found in plants and as receptors for the transforming growth factor β (TGF β) family cytokines in vertebrates, where the C-terminal domain is a signal sensor. This could also be the case for the transmembrane STPKs from prokaryotes. The C-terminal domain of PknB shows some degree of sequence similarity with the C-terminal domain of several prokaryotic STPKs, including actinobacteria (corynebacterium, streptomyces, bifidobacterium) and other

Gram-positive bacteria (listeria, bacillus, streptococcus) (Fig. 4B). These proteins display a diverse number of copies, four in PknB, of the recently described PASTA domain (for penicillin-binding-protein and serine/threonine kinase associated domain, Yeats *et al.*, 2002, TIBS 27: 438-440). This suggests that all these kinases could respond to a similar type of ligand. Actually, it has been speculated that the PASTA domains could bind unlinked peptidoglycan (Yeats *et al.*, 2002, TIBS 27: 438-440), although no experimental evidence is available to substantiate this claim. It is noteworthy that a gene coding for a putative Ser/Thr protein phosphatase is found in the same genomic region for the above mentioned organisms, suggesting a functional association with the STPK. Indeed, it has recently been described that the PrkC kinase and the PrpC phosphatase from *Bacillus subtilis* form such a couple *in vivo* with opposite effects on stationary-phase physiology (Gaidenko *et al.*, 2002, J Bacteriol 184: 6109-6114).

The catalytic domain of PknB is a functional protein kinase

The full-length recombinant PknB protein has been previously characterized and shown to possess STPK activity (Av-Gay *et al.*, 1999, Infect Immun 67: 5676-5682). To allow detailed biochemical and structural studies, we have chosen to focus on its catalytic domain. Multiple sequence alignment with members of the Ser/Thr protein kinase family and homology modelling based on available three-dimensional structures pointed to Gly 279 as the last residue in the C-terminal α -helix of the catalytic domain. Thus, the domain corresponding to amino acid residues 1-279 of PknB (PknB₁₋₂₇₉) has been produced in *E. coli* as a soluble, monomeric His-tagged protein (Fig. 5A).

The kinase activity of PknB₁₋₂₇₉ was tested either in an autophosphorylation assay or using MBP as a model substrate. Like the full-length renatured PknB (Av-Gay *et al.*, 1999, Infect Immun 67: 5676-5682), PknB₁₋₂₇₉ autophosphorylates and phosphorylates MBP (Fig. 5A). Thrombin-digested PknB₁₋₂₇₉ (i.e. without the His-Tag) is also autophosphorylated, indicating that specific autophosphorylation sites exist on the PknB catalytic domain (data not shown). Kinase activity depends on divalent cations (Fig. 5A), PknB₁₋₂₇₉ showing a clear preference for Mn²⁺ versus Mg²⁺ ions (Fig. 5B). These observations demonstrate that, when separately expressed, the catalytic domain of PknB has intrinsic kinase activity, implying that other regions of the protein (such as the juxtamembrane region) are not required to stabilize an active conformation.

The recently determined structure of the catalytic core of PknB in complex with nucleotide at 2.2 Å resolution (Ortiz-Lombardía *et al.*, 2003, *J Biol Chem* **278**: 13094-13100) and 3 Å resolution (Young *et al.*, 2003, *Nature Struct Biol* **10**: 168-174) lends further support to these observations. The PknB catalytic domain was found to be very similar to its eukaryotic homologues and shares a number of essential hallmarks first described for PKA (Knighton *et al.*, 1991, *Science* **253**: 407-414). In particular, all amino acid residues and other structural elements important for catalysis are found in their active conformation (Ortiz-Lombardía *et al.*, 2003, *J Biol Chem* **278**: 13094-13100).

Different preparations of PknB₁₋₂₇₉ produced a relatively broad complex mass peak in MALDI-TOF mass spectrometry experiments, with maximum intensity at $m/z = 32\ 538$ and smaller signals close to 80 Da, 98 Da or 160 Da apart (data not shown). After treatment with PstP or alkaline phosphatase, the peak shifted to $m/z = 32\ 291$ (the sequence-predicted average mass of uncleaved PknB₁₋₂₇₉ is 32 281 Da), indicating the removal of at least three phosphate groups linked to the protein (Figs. 6A and 6B). However, we have failed to detect any phosphorylated residue in the 3D structure of PknB (Ortiz-Lombardía *et al.*, 2003, *J Biol Chem* **278**: 13094-13100). As the whole catalytic domain (except for residues A164-T179 covering most of the activation loop) is well-defined in the electron density map, this suggests that the putative phosphoresidues should be found in the disordered or mobile parts of the protein, i.e. at the N-terminal peptide extension outside the catalytic core and/or within the activation loop itself, in agreement with the putative phosphorylation sites recently proposed for this region by Young *et al.* (2003, *Nature Struct Biol* **10**: 168-174).

PstP dephosphorylates PknB and inhibits its kinase activity

Full-length PknB has been shown to be autophosphorylated on Ser and Thr residues (Av-Gay *et al.*, 1999, *Infect Immun* **67**: 5676-5682), and the question arises whether PknB₁₋₂₇₉ could be a substrate for PstP. To address this possibility, PknB₁₋₂₇₉ was autophosphorylated with radioactive ATP before incubation with PstP in the presence or absence of MnCl₂. As shown in figure 7A, PstP is capable of dephosphorylating PknB. Phosphate hydrolysis is also reflected by the shift in PknB migration on the gel concomitant with loss of label, the lower band corresponding to dephosphorylated PknB. These differences in gel mobility were exploited to further

monitor the phosphatase reaction without previous radioactive labelling (Figure 7B). The dephosphorylation of PknB by PstP also indicates that the recombinant kinase produced in *E. coli* is phosphorylated *in vivo*.

We then asked whether the dephosphorylation of PknB could have an effect on its kinase activity. To address this question, PknB was preincubated with PstP and ATP was replaced by thio- γ ATP in the kinase reaction. The rationale for this assay resides in the ability of PknB of thiophosphorylating substrates whereas PstP is not active on these thiophosphosubstrates (data not shown). Under these conditions, the kinase activity can be measured without interference from the phosphatase activity. Figure 7C shows that prior dephosphorylation of PknB by PstP inhibits kinase activity on MBP. These results strongly suggest that the phosphorylation state of PknB is important in maintaining a fully active kinase.

Identification of two phosphothreonines in the activation loop of PknB

Mass spectrometry was used to identify the phosphoresidues detected in PknB₁₋₂₇₉. Comparison of the reverse-phase chromatograms of the trypsin digestion products of either PknB₁₋₂₇₉ or PstP-treated PknB₁₋₂₇₉ (covering 90% of the PknB₁₋₂₇₉ sequence) revealed changes in the elution pattern of some selected peptides (Fig. 8A). This observation was consistent with results from MS, in both reflector and linear modes, obtained from the corresponding whole peptide mixture (data not shown). In linear mode, two phosphopeptides could be identified from untreated PknB₁₋₂₇₉. A signal at $m/z = 1850.1$ was assigned to the His-tag peptide plus one phosphate group (calc. average mass = 1849.9 for the $[MH]^+$ peptide), and a strong signal at $m/z = 2981.3$ was assigned to the di-phosphorylated tryptic peptide A162-R189 (calc. mass = 2981.0), which includes a large fraction of the activation loop. It is noteworthy that no MS signal was detected for the non-phosphorylated A162-R189 peptide (calc. mass = 2821.1), except when PknB₁₋₂₇₉ was pretreated with a phosphatase such as alkaline phosphatase or PstP. Only in such conditions a prominent mass signal (at $m/z = 2820.8$) was observed in both linear and reflector modes.

These results were further confirmed when the separate peptide fractions were identified by MS measurements in reflector mode. Thus, peaks numbered 1 and 2 (Fig. 8A) were assigned to the monophosphorylated and unphosphorylated His-tag peptide, respectively, whereas peak 3 was assigned to the diphosphorylated A162-R189 peptide.

Upon treatment with PstP, peak 1 was reduced in size, peak 2 increased and peak 3 almost disappeared, presumably giving rise to peak 4, which corresponds to the unphosphorylated A162-R189 peptide.

Post-source decay mass spectrometry (PSD-MS) measurement of a sample from peak 3 confirmed the presence of two phosphate groups in this peptide (Fig. 8B). Definitive identification and localization of the phosphorylated residues was achieved by PSD-MS sequencing of HPLC peak 3 purified from independent batches of PknB. This analysis showed that A162-R189 peptide was phosphorylated on Thr 171 and Thr 173 (Fig. 8C). In all cases, phosphorylation of these sites was close to 100%, indicating that these threonines are systematically and homogeneously linked to a phosphate. The HPLC patterns of PknB tryptic digests were extremely constant and reproducible over the time and with different preparations of the protein. However, in some experiments a shoulder or even a small peak (just before peak 3 in Fig. 8A) could be observed, with a $m/z = 3061.1$ (data not shown). This was identified as a triphosphorylated species of the A162-R189 peptide (calc. mass = 3061.3). The third phosphosite is a serine that could not be unambiguously identified by sequencing and could correspond to either Ser 166 or Ser 169.

The above MS results identify two threonine residues from the activation loop, Thr 171 and Thr 173, as targets for PknB autophosphorylation and PstP dephosphorylation. These residues are part of a disordered region in the two PknB crystal structures (Ortiz-Lombardía *et al.*, 2003, *J Biol Chem* **278**: 13094-13100; Young *et al.*, 2003, *Nature Struct Biol* **10**: 168-174). However, inspection of the charge distribution at the molecular surface of the protein reveals an exposed cluster of basic residues that are favourably positioned to provide an anchoring site for the phosphothreonine residues (Fig. 9A). These arginine residues have partially disordered or mobile side-chains in the crystal structure, probably reflecting the absence of bound substrate. When compared with a similar cluster in PKA (Knighton *et al.*, 1991, *Science* **253**: 407-414) that binds phospho-Thr 197 in the activation loop (Fig. 9B), the positively charged region in PknB is found to cover a more extended surface area, raising the possibility of this region binding the phosphate groups of both Thr 171 and Thr 173.

Activation loop mutants of PknB

To confirm and further analyse the role of the identified phospho-threonines in PknB kinase activity, these residues were mutated to alanine, singly or in combination. The single mutants T171A, T173A and the double mutant T171/173 A were produced
5 and analysed in the MBP phosphorylation assay. Comparison of the kinetics of phosphorylation of MBP by the mutants (Fig. 10) shows that the kinase activity is affected by each single mutation to a similar extent, being 15- and 20-times less active than PknB respectively. The double mutant is 300-fold less active, suggesting a combined effect of the two phosphothreonines on kinase activity. These results confirm
10 that double phosphorylation of the activation loop is required for full kinase activity and demonstrate unambiguously the involvement of both phosphothreonines.

These mutants were also tested for the presence and localization of phosphorylated amino acid residues and the degree of phosphorylation at each site, following the same experimental protocol described above for the wild-type enzyme
15 (Table 1). The N-terminal His-tag peptide showed a consistently lower degree of phosphorylation in the three mutants when compared to the wild-type enzyme, reflecting the lower activity of the mutants. As for the wild-type enzyme, the mutant T171A is mainly diphosphorylated in the activation loop, the residues involved being now Ser 169 and Thr 173. However, phosphorylation of Ser 169 does not restore wild-
20 type activity and seems to play no functional role. On the other hand, the T173A mutant appears to be mainly monophosphorylated in Thr 171 (a much smaller HPLC signal could be assigned to a diphosphorylated species at residues Thr 171 and either Ser 166 or Ser 169). Analysis of peptides from the trypsin-digested double mutant T171/173 A demonstrated the occurrence of unphosphorylated (36%) and one monophosphorylated
25 (at either Ser 166 or Ser 169) A162-R189 peptide species. In summary, both single mutants appear still fully phosphorylated on the remaining threonine and the activity decrease of the single and double mutants did not show co-operative behaviour, suggesting that Thr 171 and Thr 173 are independent phospho-sites. Moreover, a similar decrease in kinase activity is observed upon the lost of each phosphosite, suggesting that
30 the two phosphothreonines are equally important for PknB activity.

TABLE 1

Protein	Phosphorylation status ^a and amino acid(s) involved ^b		
	His-Tag peptide	Peptide S162-R189	Phosphorylated residues
PknB ^c	45-60% non-P	close to 100% di-P	Thr171 and Thr173
	40-55% mono-P	trace of tri-P ^d	Thr171, Thr173 and (Ser169 or Ser166)
T171A	82% non-P	close to 100% di-P	Thr173 and Ser169
	18% mono-P		
T173A	87% non-P	96% mono-P	Thr171
	13% mono-P	4% di-P	Thr171 and (Ser169 or Ser166)
T171/173A	89% non-P	36% non-P	----
	11% mono-P	64% mono-P	(Ser169 or Ser166)
<p>a. Refers to relative amounts of phosphorylated species present in Nt His-Tag peptide or in peptide S162-R189 populations. Non-P, mono-P, di-P or tri-P indicates absence, one, two or three phosphate groups present respectively. Peptide samples were isolated and quantified after protein treatment with trypsin followed by HPLC and peak identification by MS, as mainly described in figures 8A to 8C and in <i>Experimental procedures</i>.</p>			
<p>b. Modified amino acid(s) by phosphorylation were localized in the sequence S162-R189 by PSD-MS as exemplified in figures 8B and 8C following the protocols described in <i>Experimental procedures</i>. The phosphorylated serine of the Nt His-Tag peptide (MGSSHHHHHSSGLVPR) was not identified.</p>			
<p>c. Samples from three independently produced batches of PknB₁₋₂₇₉ were tested.</p>			
<p>d. The phosphorylation of the third residue in the activation loop, Ser 169 or Ser 166, appears of minor importance, as the degree of phosphorylation detected was systematically low or nul.</p>			

Although *M. tuberculosis* encodes 11 STPKs (Cole *et al.*, 1998, *Nature* 393: 537-544) there is only one clear serine/threonine protein phosphatase, PstP which is a member of the PPM family (Bork *et al.*, 1996, *Protein Sci* 5: 1421-1425). We show here that its catalytic domain, PstP₁₋₂₄₀, dephosphorylates substrates previously phosphorylated on serine or threonine but not on tyrosine residues. Furthermore, its activity is strictly dependent on Mn²⁺ or Mg²⁺ ions, which is consistent with the deduced metal-ion catalysed dephosphorylation mechanism for this family (Das *et al.*, 1996, *EMBO J* 15: 6798-6809).

On the basis of its amino acid sequence, PknB (and all other mycobacterial STPKs) have been classified in the Pkn2 family of prokaryotic STPKs (Leonard *et al.*, 1998, *Genome Res* 8: 1038-1047), the cluster that most closely resembles their eukaryotic counterparts and that could have arisen by early horizontal transfer from eukarya to bacteria with complex development cycles. Recombinant full-length PknB has already been shown to possess kinase activity and autophosphorylation sites on both

serine and threonine residues (Av-Gay et al., 1999, Infect Immun 67: 5676-5682). Here we studied a construct limited to the catalytic core domain, PknB₁₋₂₇₉, as defined by sequence homology. We found that this construct is an active kinase showing that the juxtamembrane region is not required for activity, although it may still be involved in
5 further stabilization or activity regulation (see below).

Various mechanisms of eukaryotic protein kinase regulation have been described (Johnson et al., 1996, Cell 85: 149-158; Hubbard and Till, 2000, Annu Rev Biochem 69: 373-398; Huse and Kuriyan, 2002, Cell 109: 275-282). The transition
10 between active and inactive forms may occur via control of access to the catalytic and/or the substrate-binding site, or by rearrangement of structural elements involved in catalysis or substrate recognition. Furthermore, interaction with other protein domains or cofactors may take place. It is noteworthy that a large number of these regulation mechanisms involve phosphorylation/dephosphorylation (inside or outside the catalytic domain) through an autocatalytic mechanism or by the action of other intervening
15 kinases and phosphatases.

The present study shows that the catalytic domain of PknB autophosphorylates *in vitro* and is phosphorylated when expressed in *E. coli*. To see whether PknB autophosphorylation could play a regulatory role, we first identified phosphorylated residues in PknB. Mass spectrometry analysis indicated that two threonine residues of
20 the activation loop (Thr 171 and Thr 173) are systematically phosphorylated (presumably autophosphorylated). Other eukaryotic protein kinases also display two phosphorylation sites in their activation loops, such as MKK1 (two Ser residues, Alessi et al., 1994, EMBO J 0: 1610-1619) or ERK2 (a Thr and a Tyr residues, both of which have to be phosphorylated to form the active enzyme, Robbins et al., 1993, J Biol Chem
25 **268: 5097-5106**). The activation loop is a major control element of an active/inactive conformational switch in numerous kinases (Steinberg et al., 1993, Mol Cell Biol 13: 2332-2341; Johnson et al., 1996, Cell 85: 149-158; Huse and Kuriyan, 2002, Cell 109: 275-282) whose conformation often depends on their phosphorylation state (Johnson et al., 1996 Cell 85: 149-158). From its structural location, this loop may control both
30 the accessibility to the catalytic site and the binding of the substrate. A broad range of regulatory properties has been assigned to this loop, such as contributing to the proper alignment of the catalytic residues, correcting the relative orientation of the two lobes,

permitting substrate binding and/or stimulating ATP binding (Huse and Kuriyan, 2002 Cell 109: 275-282).

The inhibitory effect of dephosphorylation of PknB on its kinase activity shows that phosphorylation is required for full activity. This is further confirmed by the
5 mutagenesis study of activation loop threonine residues. Compared to the wild-type enzyme, the two single mutants, still phosphorylated on the remaining threonine, display comparable, reduced activities whereas the double-mutation further decreases the activity. Hence, Thr 171 and Thr 173 play independent and equivalent but complementary roles to reach maximal kinase activity.

10 The structural role of the phosphothreonine residues in PknB remains unexplained because the activation loop is disordered in the crystal structures (Ortiz-Lombardía et al., 2003 J Biol Chem 278: 13094-13100; Young et al., 2003 Nature Struct Biol 10: 168-174). This is not unusual in kinase structures. It has been observed both in active and inactive kinases, and does not indicate a particular phosphorylation
15 state. In some kinases, phosphorylation of the loop fixes its conformation (Johnson et al., 1996 Cell 85: 149-158) and disorder could thus indicate partial phosphorylation. However, this does not seem to be the case for PknB as the activation loop has no defined structure in the crystal structure despite complete phosphorylation of both threonines. Instead, stabilization of the PknB loop could occur upon the binding of the
20 peptide substrate through an induced-fit mechanism or by additional intra- or intermolecular interactions with other factors outside the kinase core. In any case, a positively charged region is observed in the PknB structure at the expected phosphothreonine-binding site, equivalent to a similar cluster that in PKA binds the single phosphorylated threonine, Thr197 (Figs. 9A-9B).

25 Taken together, these results strongly suggest that PknB kinase activity can be regulated by the state of phosphorylation of its activation loop *in vivo* through an autophosphorylation mechanism. Interesting observations can be drawn from the inspection of the activation loop sequences from the other *M. tuberculosis* STPKs. One or both threonines are conserved in all but two STPKs (PknG and PknI have shorter
30 loops) suggesting that these enzymes should also be regulated by autophosphorylation in their activation loops. Thus, besides the same overall 3D structure and catalytic mechanism, eukaryotic and prokaryotic kinases would also share this mechanism of

regulation, in spite of previous claims suggesting the absence of this process in prokaryotes (Motley and Lory, 1999 *Infect Immun* **67**: 5386-5394). Further investigations are obviously required to determine the physiological relevance of PknB dephosphorylation by PstP and the effect of this protein phosphatase on other kinases, in particular PknA which is present in the same operon.

Other mechanisms of kinase regulation could exist. PknB is presumed to be a transmembrane protein with a putative external ligand binding domain, an organization similar to that found in sensor histidine kinases (Parkinson, 1993 *Cell* **73**: 857-871) and receptor tyrosine kinases (Schlessinger, 2000 *Cell* **103**: 211-225). Binding of a ligand to the extracellular domain of the latter usually promotes receptor dimerization and/or a structural rearrangement that induces autophosphorylation and hence activation of the kinase domain. Interestingly, dimerization has recently been reported for PrkC (Madec et al., 2002 *Mol Microbiol* **46**: 571-586), a transmembrane STPK from *B. subtilis* with homology to PknB both in its Nt and Ct domains (Fig. 4B). Another regulation mechanism, described for both the type I TGF- β receptor serine/threonine kinase (Huse et al., 1999 *Cell* **96**: 425-436) and the ephrin receptor tyrosine kinase (EphB2) (Wybenga-Groot et al., 2001 *Cell* **106**: 745-757), involves the maintenance of an inactive state via the interaction of the juxtamembrane region with the kinase domain. Upon ligand stimulation of EphB2, the autophosphorylation of Tyr residues in the juxtamembrane sequence releases the inhibition and renders this sequence available for further interaction with SH2 domains of target proteins (Wybenga-Groot et al., 2001 *Cell* **106**: 745-757). The juxtamembrane region is missing in PknB₁₋₂₇₉. A recombinant construct of PknB corresponding to the catalytic core of the kinase plus the juxtamembrane sequence was also produced (see *Experimental procedures*). Three phosphorylation sites including Thr 294 and Thr 309 were identified in the juxtamembrane sequence (data not shown).

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

CLAIMS

1. A method for identifying a substance which modulates the activity of a pknB protein kinase, comprising:

- 5 contacting a recombinant bacterial cell with the substance, wherein the recombinant bacterial cell expresses the pknB protein kinase, and wherein the pknB protein kinase comprises the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that is at least 70% identical to SEQ ID NO: 3 and has protein kinase activity;
- measuring the pknB protein kinase activity from said bacterial cell; and
- 10 comparing the pknB protein kinase activity from the recombinant bacterial cell contacted with the substance to a bacterial cell which has not been contacted with the substance, wherein a change in protein kinase activity from the recombinant bacterial cell contacted with the substance relative to a bacterial cell which has not been contacted with the substance indicates that the substance modulates the activity of pknB
- 15 protein kinase.

2. The method of Claim 1, wherein the pknB protein kinase comprises the amino acid sequence of SEQ ID NO: 3.

3. The method of Claim 1, wherein the pknB protein kinase comprises an amino acid sequence that is at least 70% identical to SEQ ID NO: 3 and has protein kinase
- 20 activity.

4. The method of Claim 3, wherein the pknB comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 3 and has protein kinase activity.

5. The method of Claim 3, wherein the pknB comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 3 and has protein kinase activity.

- 25 6. A method for identifying a substance which modulates the activity of a pstp2 phosphatase, comprising:

 contacting a recombinant bacterial cell with the substance, wherein the recombinant bacterial cell expresses the pstp2 phosphatase, and wherein the pstp2 phosphatase comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid

30 sequence that is at least 70% identical to SEQ ID NO: 1 and has phosphatase activity;

 measuring the pstp2 phosphatase activity from the recombinant bacterial cell;

 and

comparing the pstp2 phosphatase activity from the recombinant bacterial cell contacted with the substance to a bacterial cell which has not been contacted with the substance, wherein a change in phosphatase activity from the recombinant bacterial cell contacted with the substance relative to a bacterial cell which has not been contacted with the substance indicates that the substance modulates the activity of pstp2 phosphatase.

7. The method of Claim 6, wherein the pstp2 phosphatase comprises the amino acid sequence of SEQ ID NO: 1.

8. The method of Claim 6, wherein the pstp2 phosphatase comprises an amino acid sequence that is at least 70% identical to SEQ ID NO: 1 and has phosphatase activity.

9. The method of Claim 6, wherein the pstp2 phosphatase comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has phosphatase activity.

10. The method of Claim 6, wherein the pknB comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:1 and has phosphatase activity.

11. A method of identifying an antibacterial substance, comprising:

identifying a substance according to Claims 1 to 5;

contacting a bacterial cell with the substance; and

comparing the growth, the survival or both of the bacterial cell contacted with the substance to a bacterial cell that has not been contacted with the substance, wherein a reduction in the growth, survival or both of the bacterial cell is indicative that the substance is an antibacterial substance.

12. A method of identifying an antibacterial substance, comprising:

identifying a substance according to Claims 6 to 10; and

contacting a bacterial cell with the substance;

comparing the growth, the survival or both of the bacterial cell contacted with the substance to a bacterial cell that has not been contacted with the substance, wherein a reduction in the growth, survival or both of the bacterial cell is indicative that the substance is an antibacterial substance.

13. A method for the preparation of a substance having antimicrobial activity, comprising:

identifying a substance according to Claims 1 to 5; and
synthesizing the substance.

14. A method for the preparation of a substance having antimicrobial activity,
comprising:

5 identifying a substance according to Claims 6 to 10; and
synthesizing the substance.




FIGURE 1

3/10




FIGURE 3C




FIGURE 3B




FIGURE 3A





FIGURE 5A - FIBURE 5B

6/10





FIGURE 6A - FIGURE 6B

7/10




FIGURE 7A - FIGURE 7B - FIGURE 7C




FIGURE 8B - FIGURE 8C

FIGURE 8A




FIGURE 9A - FIGURE 9B

10/10




FIGURE 10